Bajaj Healthcare Limited reported a 12.6% rise in revenue for FY26 to Rs 611.03 Cr, though Profit After Tax (PAT) fell by 50.4% to Rs 21.31 Cr, largely due to a one-time exceptional loss of Rs 33.25 Cr. The company has recommended a final dividend of Rs 1.50 per share. Its 33rd Annual General Meeting is scheduled for September 21, 2026. Management remains focused on integrating the Nashik facility acquired from Genrx Pharmaceuticals to drive future growth.
Bajaj Healthcare FY26 Performance Review
Revenue rose to Rs 611.03 Cr; PAT declined to Rs 21.31 Cr due to exceptional charges.
Reader Takeaway: Revenue growth signals strong demand, but exceptional losses and regulatory integration timing pressure short-term bottom-line performance.
What just happened
Bajaj Healthcare Limited has released its FY26 financial results, revealing a revenue increase of 12.6% to Rs 611.03 Cr compared to Rs 542.60 Cr in the previous fiscal. However, the company's Profit After Tax (PAT) witnessed a sharp decline of 50.4%, dropping to Rs 21.31 Cr from Rs 42.93 Cr. This dip was primarily driven by a one-time exceptional loss of Rs 33.25 Cr. Shareholders will vote on a final dividend of Rs 1.50 per equity share at the upcoming 33rd Annual General Meeting (AGM) scheduled for September 21, 2026.
Why this matters
The company continues to expand its global footprint, serving over 575 customers across 60 countries. While the top-line growth indicates robust market demand for its portfolio of over 250 products, the bottom-line volatility caused by the exceptional loss requires investor attention. Additionally, the debt-equity ratio has shown improvement, moving from 0.51 to 0.47, reflecting disciplined debt management during the period.
What changes now
Following the acquisition of Genrx Pharmaceuticals in April 2025, the company is awaiting final tribunal approvals to integrate the Nashik facility into its operations. Once cleared, this unit is expected to significantly boost specialized formulation capabilities. Simultaneously, the board has confirmed the re-appointment of Mr. Sajankumar R. Bajaj as Chairman & Managing Director for a three-year term through March 2029.
Risks to watch
Investors should monitor the timeline for the Nashik plant integration, as any further delays in regulatory approvals could impact expansion plans. The ability to translate recent export registrations into recurring revenue will also be critical to recovering profit margins in the coming quarters.
Context metrics
- EBITDA: Rs 111.95 Cr (up 9.9% YoY).
- Basic EPS: Rs 4.98 for FY26 compared to Rs 13.29 in FY25.
- Manufacturing: 20 active facilities with a monthly API capacity of 824 MT.